Navigation Links
Anthera's Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
Date:11/11/2008

HAYWARD, Calif., Nov. 11 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced new data on its lead product, varespladib (A-002) at the American Heart Association (AHA) Annual Conference in New Orleans, Louisiana. Anthera has completed two Phase II trials in varespladib for the treatment of coronary heart disease. At the AHA conference, Anthera and its collaborators released new data from the Phase II PLASMA-2 study, which examined varespladib (A-002) in patients with cardiovascular disease.

Results from the most recent study showed that in patients with coronary heart disease (CHD) currently on statin therapy:

-- Varespladib had a significant anti-inflammatory effect as measured by a greater than 20% relative reduction in C-reactive protein

-- Varespladib had a substantial reduction in the target enzyme and pro- inflammatory marker, secretory phospholipase A2 (84%, p<.0001)

-- Varespladib resulted in a significant reduction in LDL in CHD patients (15%, p=.0006)

-- Varespladib caused a significant reduction in small LDL particles in CHD patients

-- Varespladib established a once a day dosing schedule with a clearly defined dose response

-- Varespladib continued to have a strong safety profile, confirming results from previous studies

"We are pleased to confirm the anti-inflammatory effect and safety profile of varespladib in patients with CHD," said Dr. James E. Pennington, M.D., Executive Vice President and Chief Medical Officer of Anthera Pharmaceuticals, Inc. "The multiple therapeutic impact of varespladib's mechanism of action provides us with an opportunity to develop a first-in-class product targeting a life-threatening coronary event for which there are limited therapeutic options."

"Along with the Phase II PLASMA data presented at the American College of Cardiology earlier this year, today's data at AHA
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Anthera Presents Data on Varespladib at ATVB Meeting
2. Elekta Demonstrates Commitment to Stereotactic Innovation at EANS
3. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
4. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
5. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
6. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
7. Magnifi Group Demonstrates Industrys First Interactive Educational Program (IEP) for Spine Fellows
8. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
9. Job-related stress: NIST demonstrates fatigue effects in silicon
10. USGI Medical Demonstrates First System for Gastrotomy Closure in NOTES
11. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...eneration of ultrasmall transistors and more power...miconducting nanowires are closer to reality after...versity and the University of California at Los An...ate nanowires with layers of different materials t... is a critical requirement for making efficient tr...
(Date:11/25/2009)... to Speak at Economic Club of Canada , ... 2009 -- Ambassador to Speak at Economic Club of C...or for International Investment, and Chairman and ...raphy of David Appia go to www.investinfrance.org...eet with press to discuss recent pro-business init...
(Date:11/25/2009)... 25 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SV...announced today that it executed,a joint venture (...e,Technology Co., Ltd. (Sinovac Dalian). The JV wi...man-use vaccines. Sinovac will contribute its expe...zing world-class vaccines; the,other party will br...
(Date:11/24/2009)...man . , Whether it,s CD packaging, container...ncy Identification) are increasingly finding their...label objects or goods and identify them automatic...an read and process the data contained in the labe...uction conditions of up to 100 degrees Celsius. Bu...
Breaking Biology Technology:Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3French Ambassador for International Investment to Visit Toronto December 11 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Intelligence inside metal components 2
...mentally Responsible Site to Significantly Increas...China, CAMBRIDGE, Mass., April 22 Genzyme Corp.,...d a major new research and,development center in B...Genzyme,s ongoing global expansion and commitment ...he new facility will be used for research and deve...
...ON, N.J., April 22 Medarex, Inc.,(Nasdaq: MEDX )...t the,Morgan Stanley Global Healthcare Unplugged C..., 2008. The event will be webcast live and will be...e Medarex website at, http://www.medarex.com . An ...able,following the event., About Medarex, Medare...
...n-HDL and apoB measurement helps physicians guide ...sk patients, BIRMINGHAM, Ala., April 22 The dete...ed as valid, accurate and recommended,methods of g...patients with,cardiometabolic risk (CMR). The VAP(... commercially available advanced lipid profile tha...
Other Biology Technology:Genzyme to Build New R&D Center in Beijing 2Genzyme to Build New R&D Center in Beijing 3Genzyme to Build New R&D Center in Beijing 4Genzyme to Build New R&D Center in Beijing 5Medarex to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients 2Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients 3
(Date:11/24/2009)... Spanish . , The presence of increased body...substances in the blood, hinders the loss and main...ject of the University of Navarra conducted by Est...f Pharmacy. , The project, entitled "A nutrigene...rol of body weight and inflammation," examines how...
(Date:11/23/2009)...- The time of day matters to forest trees dealing ... a research team led by Professor Malcolm Campbell...al for research and colleagues in the department o...s. , Capitalizing on their previous work to de...eam examined how poplar trees use their 45,000 gen...
(Date:11/23/2009)...y provides "incontrovertible evidence" that the vo...atra about 73,000 years ago deforested much of cen...esearchers report. , The volcano ejected an esti...ere, leaving a crater (now the world,s largest vol...ometers wide. Ash from the event has been found in...
Breaking Biology News(10 mins):It can be predicted the reaction obese patients will have to a diet 2Time of day matters to thirsty trees, U of T researcher discovers 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2China Medicine Enhances Management Team with Appointments of New Chief Financial Officer and Finance Manager 55690 1China Medicine Enhances Management Team with Appointments of New Chief Financial Officer and Finance Manager 55690 2China Medicine Enhances Management Team with Appointments of New Chief Financial Officer and Finance Manager 55690 3China Medicine Enhances Management Team with Appointments of New Chief Financial Officer and Finance Manager 55690 4Prostate Net Announces 3A Inaugural Fore 21 Informed Decisions Golf Outing 55688 1Prostate Net Announces 3A Inaugural Fore 21 Informed Decisions Golf Outing 55688 2Prostate Net Announces 3A Inaugural Fore 21 Informed Decisions Golf Outing 55688 3Prostate Net Announces 3A Inaugural Fore 21 Informed Decisions Golf Outing 55688 4Rib X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram negative Bac 13736 1Rib X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram negative Bac 13736 2Rib X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram negative Bac 13736 3
...y hold the key to many of the challenges we face t...tion, and yet scientists estimate that they have d...pecies. , Helping students delve into such unchar... their interest and motivation in science and rese...ter. The Center, to be launched later this month, ...
..., CA (March 20, 2009) A rigorous environmental cle...methicillin-resistant Staphylococcus aureus (MRS...ital intensive care units (ICUs), according to a n...he Society for Healthcare Epidemiology of America ...ced cleaning protocol reduced the spread of MRSA t...
.... Scientists at Duke University Medical Center ha...ut some smokers at significantly higher risk of de...PD). , The findings come from the first-ever gen...t those who carry the markers may be able to reduc... symptoms of COPD occur. , "The public health mes...
Other Biology News:Bioscience institutions come together to launch Microlife Discovery Center for area students 2Bioscience institutions come together to launch Microlife Discovery Center for area students 3Environmental cleaning intervention reduces transmission of multidrug-resistant organisms in ICUs 2Genetic irregularities linked to higher risk of COPD among smokers 2
Rhesus Monkey IFN-Alpha from Cell Sciences
Bovine DNP-BSA (Bovine Serum Albumin), BSA (Bovine Serum Albumin) conjugated/tagged from Biosearch Technologies
Bovine NIP-BSA (Bovine Serum Albumin), BSA (Bovine Serum Albumin) conjugated/tagged from Biosearch Technologies
Amino Acid Analysis from Bio-Synthesis
Biology Products: